Spark Therapeutics, Inc. (ONCE) Position Lowered by Ameriprise Financial Inc.

Ameriprise Financial Inc. lessened its position in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 18.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 195,575 shares of the biotechnology company’s stock after selling 43,610 shares during the quarter. Ameriprise Financial Inc. owned about 0.63% of Spark Therapeutics worth $11,685,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 2,449 shares in the last quarter. Pacad Investment Ltd. raised its stake in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 1,500 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of Spark Therapeutics during the 1st quarter worth approximately $227,000. KCG Holdings Inc. raised its stake in shares of Spark Therapeutics by 9.4% during the 1st quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 538 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Spark Therapeutics by 16.8% during the 2nd quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after acquiring an additional 1,286 shares in the last quarter. Hedge funds and other institutional investors own 77.84% of the company’s stock.

Spark Therapeutics, Inc. (ONCE) opened at 85.67 on Tuesday. Spark Therapeutics, Inc. has a 52 week low of $35.07 and a 52 week high of $91.00. The firm’s 50-day moving average is $85.86 and its 200-day moving average is $85.86. The firm’s market cap is $2.68 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.04) EPS. On average, equities analysts anticipate that Spark Therapeutics, Inc. will post ($7.67) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://ledgergazette.com/2017/10/10/spark-therapeutics-inc-once-position-lowered-by-ameriprise-financial-inc.html.

Several research firms recently commented on ONCE. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $111.00 price objective on shares of Spark Therapeutics in a research note on Friday. SunTrust Banks, Inc. reiterated a “buy” rating and set a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a research note on Monday, September 25th. Barclays PLC began coverage on shares of Spark Therapeutics in a research note on Wednesday, September 6th. They set an “overweight” rating and a $104.00 price objective for the company. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a research note on Friday, August 25th. Finally, Royal Bank Of Canada began coverage on shares of Spark Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $100.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $88.38.

In other news, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the transaction, the insider now directly owns 215,000 shares of the company’s stock, valued at approximately $18,524,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel Faga sold 3,000 shares of Spark Therapeutics stock in a transaction on Monday, July 24th. The shares were sold at an average price of $70.00, for a total transaction of $210,000.00. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at $210,000. The disclosure for this sale can be found here. Insiders sold a

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Arbitrage SA raised its stake in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after acquiring an additional 2,449 shares in the last quarter. Pacad Investment Ltd. raised its stake in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 1,500 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of Spark Therapeutics during the 1st quarter worth approximately $227,000. KCG Holdings Inc. raised its stake in shares of Spark Therapeutics by 9.4% during the 1st quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after acquiring an additional 538 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Spark Therapeutics by 16.8% during the 2nd quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after acquiring an additional 1,286 shares in the last quarter. Hedge funds and other institutional investors own 77.84% of the company’s stock.

Spark Therapeutics, Inc. (ONCE) opened at 85.67 on Tuesday. Spark Therapeutics, Inc. has a 52 week low of $35.07 and a 52 week high of $91.00. The firm’s 50-day moving average is $85.86 and its 200-day moving average is $85.86. The firm’s market cap is $2.68 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.04) EPS. On average, equities analysts anticipate that Spark Therapeutics, Inc. will post ($7.67) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://ledgergazette.com/2017/10/10/spark-therapeutics-inc-once-position-lowered-by-ameriprise-financial-inc.html.

Several research firms recently commented on ONCE. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $111.00 price objective on shares of Spark Therapeutics in a research note on Friday. SunTrust Banks, Inc. reiterated a “buy” rating and set a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a research note on Monday, September 25th. Barclays PLC began coverage on shares of Spark Therapeutics in a research note on Wednesday, September 6th. They set an “overweight” rating and a $104.00 price objective for the company. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a research note on Friday, August 25th. Finally, Royal Bank Of Canada began coverage on shares of Spark Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $100.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seventeen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $88.38.

In other news, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the transaction, the insider now directly owns 215,000 shares of the company’s stock, valued at approximately $18,524,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel Faga sold 3,000 shares of Spark Therapeutics stock in a transaction on Monday, July 24th. The shares were sold at an average price of $70.00, for a total transaction of $210,000.00. Following the completion of the transaction, the insider now directly owns 3,000 shares in the company, valued at $210,000. The disclosure for this sale can be found here. Insiders sold a total of 1,333,195 shares of company stock worth $109,070,506 over the last ninety days. Corporate insiders own 7.30% of the company’s stock.

Spark Therapeutics Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply